Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cavan Disease - Overview
Cavan Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cavan Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cavan Disease - Companies Involved in Therapeutics Development
Aspa Therapeutics Inc
Orphan Star Therapeutics LLC
Pfizer Inc
Cavan Disease - Drug Profiles
BBP-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 2 to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Aspartoacylase Replacement for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cavan Disease - Dormant Projects
Cavan Disease - Discontinued Products
Cavan Disease - Product Development Milestones
Featured News & Press Releases
Oct 22, 2019: BridgeBio Pharma presents on its Central Nervous drug candidate BBP-812 at the European Society of Gene and Cell Therapy Conference
Nov 09, 2017: New gene therapy developed with UNSW researchers targets brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Canavan Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Canavan Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Canavan Disease - Pipeline by Aspa Therapeutics Inc, H1 2020
Canavan Disease - Pipeline by Orphan Star Therapeutics LLC, H1 2020
Canavan Disease - Pipeline by Pfizer Inc, H1 2020
Canavan Disease - Dormant Projects, H1 2020
Canavan Disease - Discontinued Products, H1 2020